Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.
Langenbecks Arch Surg. 2023 May 24;408(1):207. doi: 10.1007/s00423-023-02948-8.
Hyperthermic intraperitoneal chemotherapy (HIPEC) is accompanied with an increased risk of acute kidney injury (AKI). Whether AKI is induced by chemotoxicity or hyperthermia-related changes in renal perfusion remains controversial. The influence of HIPEC on renal perfusion has not been evaluated in patients yet.
Renal blood perfusion was assessed in ten patients treated with HIPEC by intraoperative renal Doppler pulse-wave ultrasound. Ultrasound (US) examinations were performed pre-, intra-, and postoperative with analyses of time-velocity curves. Patient demographics, surgical details, and data regarding renal function were recorded perioperatively. For evaluation of renal Doppler US to predict AKI, patients were divided in two groups with (AKI +) and without (AKI -) kidney injury.
Throughout HIPEC perfusion, neither significant nor consistent changes in renal perfusion could be observed. Postoperative AKI occurred in 6 of 10 participating patients. Intraoperative renal resistive index (RRI) values > 0.8 were observed in one patient developing stage 3 AKI according KDIGO criteria. At 30 min in perfusion, RRI values were significantly higher in AKI + patients.
AKI is a common and frequent complication after HIPEC, but underlying pathophysiology remains elusive. High intraoperative RRI values may indicate an increased risk of postoperative AKI. Present data challenges the relevance of hyperthermia-derived hypothesis of renal hypoperfusion with prerenal injury during HIPEC. More attention should be drawn towards chemotoxic-induced hypothesis of HIPEC-induced AKI and caution applying regimens containing nephrotoxic agents in patients. Further confirmatory and complementary studies on renal perfusion as well as pharmacokinetic HIPEC studies are required.
腹腔内热灌注化疗(HIPEC)伴随着急性肾损伤(AKI)风险增加。AKI 是由化学毒性引起的,还是与肾灌注的高热相关变化有关,目前仍存在争议。HIPEC 对患者肾灌注的影响尚未得到评估。
通过术中肾多普勒脉冲波超声评估 10 例接受 HIPEC 治疗的患者的肾血流灌注。超声(US)检查在术前、术中、术后进行,并对时间-速度曲线进行分析。记录围手术期患者的人口统计学、手术细节和肾功能数据。为了评估肾多普勒 US 预测 AKI 的能力,将患者分为发生(AKI+)和未发生(AKI-)肾损伤的两组。
在 HIPEC 灌注过程中,未观察到肾灌注的显著或一致变化。10 名参与患者中有 6 名术后发生 AKI。根据 KDIGO 标准,1 名发生 3 期 AKI 的患者术中肾阻力指数(RRI)值>0.8。在灌注的 30 分钟时,AKI+患者的 RRI 值显著更高。
AKI 是 HIPEC 后常见且频繁发生的并发症,但潜在的病理生理学仍不清楚。术中高 RRI 值可能表明术后 AKI 的风险增加。目前的数据挑战了高热相关假说,即肾灌注减少伴术前损伤与 HIPEC 期间的肾灌注减少有关。应更加关注化学毒性引起的假说,即 HIPEC 引起的 AKI,并谨慎在患者中应用含有肾毒性药物的方案。需要进一步进行肾灌注的确认性和补充性研究以及药代动力学 HIPEC 研究。